CN114728974B - 作为btk抑制剂的吡咯并嘧啶类化合物及其应用 - Google Patents
作为btk抑制剂的吡咯并嘧啶类化合物及其应用 Download PDFInfo
- Publication number
- CN114728974B CN114728974B CN202080078768.4A CN202080078768A CN114728974B CN 114728974 B CN114728974 B CN 114728974B CN 202080078768 A CN202080078768 A CN 202080078768A CN 114728974 B CN114728974 B CN 114728974B
- Authority
- CN
- China
- Prior art keywords
- compound
- added
- reaction
- acid
- synthesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311079865.7A CN117551103A (zh) | 2019-11-13 | 2020-11-13 | 作为btk抑制剂的吡咯并嘧啶类化合物及其应用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911109773 | 2019-11-13 | ||
| CN2019111097732 | 2019-11-13 | ||
| CN201911288492 | 2019-12-13 | ||
| CN2019112884928 | 2019-12-13 | ||
| CN202010096582 | 2020-02-17 | ||
| CN2020100965823 | 2020-02-17 | ||
| CN2020107112709 | 2020-07-22 | ||
| CN202010711270 | 2020-07-22 | ||
| PCT/CN2020/128597 WO2021093839A1 (zh) | 2019-11-13 | 2020-11-13 | 作为btk抑制剂的吡咯并嘧啶类化合物及其应用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311079865.7A Division CN117551103A (zh) | 2019-11-13 | 2020-11-13 | 作为btk抑制剂的吡咯并嘧啶类化合物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114728974A CN114728974A (zh) | 2022-07-08 |
| CN114728974B true CN114728974B (zh) | 2023-09-19 |
Family
ID=75912541
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080078768.4A Active CN114728974B (zh) | 2019-11-13 | 2020-11-13 | 作为btk抑制剂的吡咯并嘧啶类化合物及其应用 |
| CN202311079865.7A Withdrawn CN117551103A (zh) | 2019-11-13 | 2020-11-13 | 作为btk抑制剂的吡咯并嘧啶类化合物及其应用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311079865.7A Withdrawn CN117551103A (zh) | 2019-11-13 | 2020-11-13 | 作为btk抑制剂的吡咯并嘧啶类化合物及其应用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12378253B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4059935A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7473642B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102793446B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN114728974B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021093839A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4234558A4 (en) * | 2020-12-07 | 2024-10-23 | Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. | PYRROLOPYRIDINE COMPOUND AND APPLICATION THEREOF |
| CN114761410B (zh) * | 2021-04-06 | 2023-08-25 | 广州必贝特医药股份有限公司 | 吡咯并嘧啶酮类化合物及其应用 |
| JP7645573B2 (ja) * | 2021-05-12 | 2025-03-14 | ジャージアン・ロングチャーム・バイオ-テック・ファーマ・カンパニー・リミテッド | ピロロピリミジン類化合物の結晶形およびその調製方法 |
| CN117500806A (zh) * | 2021-05-28 | 2024-02-02 | 默沙东有限责任公司 | Btk抑制剂及其中间体的合成 |
| EP4448523A1 (en) | 2021-12-14 | 2024-10-23 | Crossfire Oncology Holding B.V. | Macrocyclic btk inhibitors |
| CN115894500B (zh) * | 2022-11-02 | 2024-05-28 | 中国药科大学 | 一种作为btk激酶抑制剂的化合物及其制备方法与用途 |
| CN118702697A (zh) * | 2023-03-18 | 2024-09-27 | 山东新时代药业有限公司 | 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法 |
| CN116375715B (zh) * | 2023-04-06 | 2025-04-04 | 中国药科大学 | 一种作为非共价btk激酶抑制剂的化合物及其生物用途 |
| WO2024246287A1 (en) | 2023-06-02 | 2024-12-05 | Crossfire Oncology Holding B.V. | Medical use of a macrocyclic reversible btk inhibitor |
| WO2024245578A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor |
| WO2024245577A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor |
| WO2024256568A1 (en) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Salt and crystal forms of a macrocyclic btk inhibitor |
| WO2024256574A1 (en) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Process for preparing macrocyclic btk inhibitors |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101594871A (zh) * | 2006-05-26 | 2009-12-02 | 诺瓦提斯公司 | 吡咯并嘧啶化合物及其用途 |
| EP3042903A1 (en) * | 2015-01-06 | 2016-07-13 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| WO2017111787A1 (en) * | 2015-12-23 | 2017-06-29 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
| CN109890821A (zh) * | 2016-08-24 | 2019-06-14 | 艾科尔公司 | 氨基-吡咯并嘧啶酮化合物及其使用方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20170311T1 (hr) * | 2012-08-06 | 2017-04-21 | Acea Biosciences Inc. | Novi spojevi pirolopirimidina kao inhibitori protein kinaza |
-
2020
- 2020-11-13 CN CN202080078768.4A patent/CN114728974B/zh active Active
- 2020-11-13 EP EP20887944.5A patent/EP4059935A4/en active Pending
- 2020-11-13 KR KR1020227018702A patent/KR102793446B1/ko active Active
- 2020-11-13 JP JP2022528124A patent/JP7473642B2/ja active Active
- 2020-11-13 US US17/776,873 patent/US12378253B2/en active Active
- 2020-11-13 CN CN202311079865.7A patent/CN117551103A/zh not_active Withdrawn
- 2020-11-13 WO PCT/CN2020/128597 patent/WO2021093839A1/zh not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101594871A (zh) * | 2006-05-26 | 2009-12-02 | 诺瓦提斯公司 | 吡咯并嘧啶化合物及其用途 |
| EP3042903A1 (en) * | 2015-01-06 | 2016-07-13 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| WO2017111787A1 (en) * | 2015-12-23 | 2017-06-29 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
| CN109890821A (zh) * | 2016-08-24 | 2019-06-14 | 艾科尔公司 | 氨基-吡咯并嘧啶酮化合物及其使用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114728974A (zh) | 2022-07-08 |
| JP2023506691A (ja) | 2023-02-20 |
| EP4059935A4 (en) | 2024-02-28 |
| KR20220097455A (ko) | 2022-07-07 |
| US20230357248A1 (en) | 2023-11-09 |
| CN117551103A (zh) | 2024-02-13 |
| WO2021093839A1 (zh) | 2021-05-20 |
| US12378253B2 (en) | 2025-08-05 |
| EP4059935A1 (en) | 2022-09-21 |
| KR102793446B1 (ko) | 2025-04-09 |
| JP7473642B2 (ja) | 2024-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102793446B1 (ko) | Btk 억제제로서의 피롤로피리미딘 화합물 및 이의 용도 | |
| EP3741756B1 (en) | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor | |
| JP7313492B2 (ja) | Dna-pk阻害剤としてのキノリン及びシンノリン誘導体 | |
| EP3753937B1 (en) | Atr inhibitor and application thereof | |
| CN113993860B (zh) | 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物 | |
| CN117083281A (zh) | 嘧啶并杂环类化合物及其应用 | |
| CN109790148A (zh) | 具有usp30抑制剂活性的氰基取代的杂环 | |
| WO2021115401A1 (zh) | 具有大环结构的含氟并杂环衍生物及其用途 | |
| JP2023526490A (ja) | フルオロピロロピリジン系化合物及びその使用 | |
| CN114008046A (zh) | 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物 | |
| WO2020156568A1 (zh) | 作为pd-l1免疫调节剂的氟乙烯基苯甲酰胺基化合物 | |
| CN116438175B (zh) | 苯并脲环衍生物及其制备方法和应用 | |
| CN117561265B (zh) | 二甲基取代的噻唑并内酰胺类化合物及其应用 | |
| HK40080199A (en) | Pyrrolopyrimidine compound as btk inhibitor and use thereof | |
| US20230183230A1 (en) | Compounds containing benzosultam | |
| CN117279923A (zh) | 六元杂芳并脲环的衍生物及其应用 | |
| CN117561266A (zh) | 噻唑并内酰胺并螺杂环类化合物及其应用 | |
| TWI795129B (zh) | 吡啶并嘧啶酮類化合物 | |
| CN115894376B (zh) | 一种芳香族酰胺类化合物、药物组合物及其用途 | |
| CN113286594B (zh) | 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用 | |
| JP2020523369A (ja) | Gls1阻害剤としての化合物 | |
| CN118139865A (zh) | 吡咯并吡唑螺环化合物 | |
| CN116490504A (zh) | 吡咯并吡啶类化合物及其应用 | |
| WO2023207991A1 (zh) | 稠合喹唑啉类化合物及其应用 | |
| CN119998273A (zh) | 苄氨基喹啉类化合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220916 Address after: 310018 room 1-1203, Heda Medicine Valley Center, No. 291, Fucheng Road, Xiasha street, Qiantang new area, Hangzhou, Zhejiang Applicant after: Zhejiang Longchuan Biomedical Technology Co.,Ltd. Address before: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province Applicant before: Nanjing Mingde New Drug Development Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |